Minjares Ramon O, Martin Paul, Carrion Andres F
Department of Internal Medicine, University of Miami Miller School of Medicine, 1611 NW 12th Avenue, Suite 600-D, Miami, FL 33136, USA.
Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, 1611 NW 12th Avenue, Suite 600-D, Miami, FL 33136, USA.
Clin Liver Dis. 2022 May;26(2):323-340. doi: 10.1016/j.cld.2022.01.006. Epub 2022 Apr 1.
Improved survival after liver transplantation has led to an aging cohort of recipients at risk of renal dysfunction. The etiology of renal dysfunction is typically multifactorial; calcineurin inhibitors nephrotoxicity, pretransplant renal dysfunction, and perioperative acute kidney injury are important risk factors. Metabolic complications such as hypertension, diabetes mellitus, and metabolic-associated fatty liver disease also contribute to the development of renal disease. Most LT recipients will eventually develop some degree of renal dysfunction. Criteria to select candidates for simultaneous liver and kidney transplantation have been established. Both delayed introduction of CNIs and renal-sparing immunosuppressive regimens may reduce progression of renal dysfunction.
肝移植术后生存率的提高导致接受者群体老龄化,面临肾功能障碍风险。肾功能障碍的病因通常是多因素的;钙调神经磷酸酶抑制剂肾毒性、移植前肾功能障碍和围手术期急性肾损伤是重要的危险因素。高血压、糖尿病和代谢相关脂肪性肝病等代谢并发症也会导致肾脏疾病的发生。大多数肝移植受者最终会出现一定程度的肾功能障碍。同时进行肝肾移植的候选者选择标准已经确立。延迟使用钙调神经磷酸酶抑制剂和肾脏保护免疫抑制方案都可能减缓肾功能障碍的进展。